NASDAQ:CTIC - CTI BioPharma Stock Price, News & Analysis

$0.71
+0.03 (+4.41 %)
(As of 08/21/2019 04:00 PM ET)
Today's Range
$0.68
Now: $0.71
$0.71
50-Day Range
$0.64
MA: $0.74
$0.84
52-Week Range
$0.60
Now: $0.71
$2.30
Volume120,700 shs
Average Volume289,912 shs
Market Capitalization$41.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.29 million
Book Value$0.91 per share

Profitability

Net Income$-29,320,000.00
Net Margins-225.01%

Miscellaneous

Employees46
Market Cap$41.17 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.


CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma shares reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) posted its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.19). The biopharmaceutical company had revenue of $0.42 million for the quarter. CTI BioPharma had a negative return on equity of 77.77% and a negative net margin of 225.01%. View CTI BioPharma's Earnings History.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for CTI BioPharma.

What price target have analysts set for CTIC?

2 brokerages have issued 1 year target prices for CTI BioPharma's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate CTI BioPharma's stock price to reach $4.00 in the next year. This suggests a possible upside of 463.4% from the stock's current price. View Analyst Price Targets for CTI BioPharma.

What is the consensus analysts' recommendation for CTI BioPharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CTI BioPharma.

Has CTI BioPharma been receiving favorable news coverage?

News stories about CTIC stock have been trending positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CTI BioPharma earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for CTI BioPharma.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the folowing people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)
  • Mr. Ed Bell, Sr. Director of Investor Relations

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (6.73%), Renaissance Technologies LLC (2.75%), Vanguard Group Inc. (1.82%), Northern Trust Corp (0.93%), Fosun International Ltd (0.79%) and JPMorgan Chase & Co. (0.64%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.

Which institutional investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Stonepine Capital Management LLC, JPMorgan Chase & Co. and Northern Trust Corp. View Insider Buying and Selling for CTI BioPharma.

Which institutional investors are buying CTI BioPharma stock?

CTIC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Fosun International Ltd, Jane Street Group LLC and SG Americas Securities LLC. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $0.71.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $41.17 million and generates $26.29 million in revenue each year. CTI BioPharma employs 46 workers across the globe.View Additional Information About CTI BioPharma.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is http://www.ctibiopharma.com/.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]


MarketBeat Community Rating for CTI BioPharma (NASDAQ CTIC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  446
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2019 by MarketBeat.com Staff

Featured Article: Front-End Load

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel